Swiss major Roche announced its financials today, and buried within its pipeline updates the company announced it was dumping a host of early- and late-stage candidates.
In phase 3 it has removed lampalizumab (RG7417), which last fall flopped two tests: Chroma and Spectri, which were assessing the drug in geographic atrophy (GA) due to age-related macular degeneration (AMD), and secondary to AMD.
Jefferies had tipped this drug to top out at $2 billion a year, but it has now been relegated to the Roche dustbin.
RELATED: Phase 3 fail puts Roche blockbuster-to-be on the critical list
Further back in phase 1 it’s also canning work on two cancer drugs: RG7986, an antibody drug conjugate for refractory B-cell non-Hodgkin’s lymphoma, and RG6047, which was being tested in metastatic estrogen receptor-positive, HER2-negative breast cancer.
The B-cell med had in fact been developed via Seattle Genetics' ADC tech. RG7604, meanwhile, is a small molecule PI3 kinase inhibitor.
And finally, it’s also curtains for RG7203, a small molecule inhibitor of phosphodiesterase 10A (PDE10A) for the treatment of schizophrenia.
RELATED: Roche dumps lead asset from its $725M Seragon buy